Anand Rathi Wealth Limited announces with profound sorrow the sudden demise of Mr. Chethan Shenoy, Head of Product & Research, on November 8, 2025, due to cardiac arrest. Mr. Shenoy’s contributions and leadership were integral to the company’s growth, and his loss will be deeply felt by employees, clients, and stakeholders. The company extends its heartfelt condolences to his family.

Sudden Passing of Key Executive

It is with deep regret that Anand Rathi Wealth Limited announces the untimely passing of Mr. Chethan Shenoy, who served as the Head of Product & Research. His demise occurred on November 8, 2025, due to a cardiac arrest.

Impact and Condolences

Mr. Shenoy’s dedication and strong leadership were invaluable to the company. His contributions played a significant role in the growth and success of Anand Rathi Wealth Limited. The company mourns his loss and extends its deepest sympathy to his family during this difficult time.

Details of Demise

The announcement confirms that Mr. Shenoy’s passing is classified as a death as per regulatory requirements.

Source: BSE

Shyam Metalics reported strong financial results for Q2 & H1 FY26. Revenue grew by 23% in Q2. The company highlighted operational efficiencies and strategic expansions contributing to higher ROCE and lower CAPEX requirements. They also emphasized focus on value-added products and deleveraging the balance sheet to provide flexibility in growth. PAT positive since 2005.

Financial Performance Highlights

Shyam Metalics announced a strong financial performance for the second quarter and first half of fiscal year 2026:

• Q2 FY26:

Revenue: Rs. 4,457 Cr, EBITDA: Rs. 609 Cr, PAT: Rs. 260 Cr.

Revenue growth in Q2 was reported at 23% and volume growth at 24%.

• H1 FY26:

Revenue: Rs. 8,876 Cr, EBITDA: Rs. 1,242 Cr, PAT: Rs. 551 Cr.

Strategic Growth & Expansion

The company is focused on strategically expanding into diversified, value-added product segments. A key focus is on increasing capacity in a cost-effective manner. Some key initiatives:

• Expanding into value-added product segments with higher ROCE and lower CAPEX.
• Continued focus on operational efficiencies to drive profitability.
• Maintaining a conservative capital structure with debt to equity capped at 0.5x.

Capital Expenditure & Projects

Shyam Metalics has committed to funding CAPEX through internal accruals. Capex incurred till Q2 FY26 reached Rs. 7,529 crores, representing 80% of total envisaged CAPEX.

Credit Rating

The company’s long-term credit rating has been upgraded to CRISIL AA+ (Stable), the highest among peer groups, reflecting a strong financial risk profile.

Source: BSE

Poly Medicure announced its unaudited financial results for the second quarter of FY26. Consolidated revenue grew by 5.7%, with domestic revenue up by 16.9%. The company completed acquisitions of PendraCare Group and Citieffe Group. Operating EBITDA margin stood at 26.8%. The company maintains a strong liquidity position with ₹1,109.1 Crs in net cash as of September 30, 2025.

Financial Performance

Poly Medicure reported a consolidated revenue growth of 5.7% for Q2 FY26, with domestic revenue showing a stronger growth of 16.9%. The Operating EBITDA margin for the quarter was 26.8%.

Key Highlights for Q2 FY26

• Completed acquisitions of PendraCare Group (Netherlands – Cardiology) and Citieffe Group (Italy – Orthopaedics).
• Launched “Polymed Academy of Clinical Excellence” (PACE).
• Launched 8 new products.

Consolidated Financial Results Summary

Key figures for Q2 FY26 (July-September):

• Revenue from Operations: ₹443.9 Crs (up 5.7% year-over-year)
• Gross Profit: ₹308.2 Crs (up 7.2% year-over-year)
• Operating EBITDA: ₹118.8 Crs (up 2.5% year-over-year)
• PAT: ₹91.8 Crs (up 5.0% year-over-year)

Balance Sheet Highlights

• Net Cash: ₹1,109.1 Crs as of September 30, 2025

Segment Performance

• Infusion Therapy: ₹273.5 Crs
• Renal: ₹44.2 Crs
• Others: ₹125.9 Crs

Shareholding Pattern

As of September 30, 2025:

• Promoters & Promoter Group: 62.4%
• Foreign Portfolio Investors: 9.8%

Source: BSE

Apollo Hospitals Enterprise Limited has received in-principle approval from the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for issuing and allotting a maximum of 21,56,770 equity shares under its Employee Stock Option Plan 2024. These shares, valued at Rs. 5/- each, will be offered to eligible employees of the company, reinforcing its commitment to employee welfare.

ESOP Approval Granted

Apollo Hospitals Enterprise Limited announced that it has secured in-principle approval from both the BSE and NSE for its Employee Stock Option Plan (ESOP) 2024. This approval allows the company to proceed with issuing and allotting shares to its employees under the terms of the plan.

Details of the ESOP

The approval covers a maximum of 21,56,770 equity shares, each with a face value of Rs. 5/-. These shares are intended to be allotted to the company’s employees as part of the Apollo Hospitals Enterprise Limited Employee Stock Option Plan 2024 (Apollo ESOP 2024).

Official Communication

The company officially communicated that the approval letters from BSE (reference number DCS/ESOP/IP/TS/3877/2025-26) and NSE (reference number NSE/LIST/51179), both dated November 7, 2025, have been received. These approvals mark a significant step forward in the implementation of the ESOP, allowing the company to reward and incentivize its employees through equity participation.

Source: BSE

Home First Finance Company India Limited reported a 26.3% year-over-year increase in Assets Under Management (AUM), reaching ₹14,178 crores. The company continues to broaden its distribution footprint and sees strength in digital adoption, with 83% of approvals facilitated via the account aggregator framework. While delinquencies saw a slight uptick, the company anticipates improvements and is focused on maintaining healthy asset quality metrics.

Financial Performance Highlights

Home First Finance Company India Limited announced its Q2 FY26 results, showcasing strong growth and continued strategic expansion:

• AUM Growth: Increased by 26.3% year-over-year and 5.2% quarter-over-quarter, reaching ₹14,178 crores.
• Total Income: Rose to ₹479 crores, reflecting a 28% year-over-year increase and 5.2% quarter-over-quarter growth.
• Profit After Tax: Increased to ₹132 crores, a 43% year-over-year and 10.9% quarter-over-quarter increase.
• Net Interest Margin (NIM): Improved to 5.4% in Q2, up from 5.2% in the previous quarter.

Strategic Expansion and Digital Adoption

Home First continues to strategically expand its distribution network and strengthen its digital capabilities:

• The company has expanded its reach from 249 to 366 touchpoints over the last three years, marking a 47% increase.
• Branch Count: Increased from 101 to 163 branches.
• Digital Approvals: 83% of approvals in Q2 were facilitated via the account aggregator framework.
• Digital Loan Fulfillment: Over 80% of loans are digitally fulfilled through e-agreements and e-NACH mandates.
• Mobile App Adoption: 96% of customers registered on the mobile app, with 87% of service requests now raised digitally.

Asset Quality and Provisions

Home First is closely monitoring asset quality and maintaining a conservative approach to provisioning:

• 1+ DPD: Stood at 5.5%.
• 30+ DPD: Stood at 3.7%.
• Gross Stage 3: Stood at 1.9%.
• Provision Coverage: Total provision coverage is 40.8%.
• Credit Cost: 40 bps for Q2.

Capital Adequacy and Funding

• Capital to Risk-Weighted Assets Ratio: Stood at 48.4% as of September 2025.
• Net Worth: Increased to ₹4,014 crores, a 75% year-over-year increase.
• Book Value per Share: ₹388 as of September 2025.

Source: BSE